Kim A. Papp September 13, 2021
Dermatol Ther (Heidelb). 2021 Sep 11. [OPEN Access] INTRODUCTION: Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapies and managing medication overlap, considerations for special populations of patients with AD, and management of potential adverse events.   METHODS: This article aims to review the literature addressing several practical management issues related to dupilumab use for AD and to provide a framework for clinical decision-making in these circumstances and sub-populations. Each statement was reviewed, revised and voted on by authors to provide their level of agreement and degree of uncertainty for each statement.   RESULTS: An agreement level > 80% was achieved for all of the statements.   CONCLUSION: The expert panel provides statements considering the practical management of patients with AD taking dupilumab to inform clinical decision-making in specific but frequently encountered clinical situations.  PMID:34510403 | DOI:10.1007/s13555-021-00586-w

Full text access may require purchase from the publisher, or a login through your institution's library or computer network.